Additionally, several clinical challenges need to be addressed, including the use of MET inhibitors for treating brain metastases and investigating the role of ICIs, either alone or in combination with anti-MET agents, in patients with MET-altered NSCLC. Here, MET is linked to non-small cell lung carcinoma.